WAM
NVNO

Wolverine Asset Management’s enVVeno Medical NVNO Stock Holding History

Wolverine Asset Management’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed -$567 – 1846
2025
Q4 		$567 Hold
51
– – ﹤0.01% 1588
2025
Q3 		$1.6K Buy
+51
New +$5.21K ﹤0.01% 1484

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wolverine Asset Management's NVNO Position: Q1 2026 in Review

Wolverine Asset Management sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 51 shares — an estimated $567 sold.

Wolverine Asset Management first reported a position in NVNO in Q3 2025 and held it in 2 quarters. The position peaked at $1.6K in Q3 2025. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Wolverine Asset Management reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 51 enVVeno Medical shares in Q1 2026, an estimated $567.
  • Wolverine Asset Management first reported a position in enVVeno Medical in Q3 2025 and held it in 2 quarters.
  • Wolverine Asset Management's enVVeno Medical position peaked at $1.6K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.